Variants of TACE pro-domain as TNF-A inhibitor and their medical use
AssigneeYeda Research and Development Co. Ltd.
InventorsIrit Sagi, Eitan Wong, Ran Afik
Life of this patent
Estimating the term…
Abstract
A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.
Claims6
A method of treating an inflammatory disease, the method comprising administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-α converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a substitution at each of the sites R58, R211 and C184 thereby rendering said polypeptide resistant to furin degradation, said polypeptide being capable of downregulating an activity of TACE, wherein the numbering of the substitution corresponds to the full length human TACE enzyme.
Dependencies are inferred from the claim text.